Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of GZR18 injection in obese/overweight Chinese adults
CTR20231695Phase 2Completed
- Sponsor
- Gannex Pharma Co., Ltd.
- Start
- Jun 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obesity and Overweight comparing GZR18 with Placebo (2 arms). Primary endpoint: Percent change in body weight from baseline at week 30. Started Jun 2023; status: completed.
02
Drugs
bofanglutide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20231695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231695.